American Association of Clinical Endocrinologists (AACE)

For diabetes patients being diagnosed with the disease is a life altering event. How they are informed about their condition can make a world of difference in how they approach their treatment.

The use of genetic testing in endocrinology may be new, but in the future it could prove to be a valuable tool as the medical community looks to move beyond gastric bypass and other treatments for obesity and other conditions.

In early testing the bionic pancreas has shown strong results for treating patients with type 1 diabetes. Over the next two years more work will go into streamlining the device and further testing in hopes of receiving FDA approval.

The final version of the bionic pancreas will be a more compact device but the first version is a combination mobile technology and existing glucose monitors and insulin pumps.

Patients with type 1 diabetes could get a powerful new treatment tool as work continues on the development of a bionic pancreas. The device is still undergoing testing and tweaking but initial results have shown promise from an early model.

Timothy Garvey, MD, FACE, Professor at the University of Alabama at Birmingham, and Chair of the AACE Obesity Scientific Committee, provided an overview of the AACE Module and Tool Kit for Obesity Medicine at the 24th Annual Scientific & Clinical Congress in Nashville, TN.

Review of existing guidelines for cardiovascular disease and diabetes shows a continuing reliance on experience and expert opinion.

Enhancing beta cell regeneration and modulating autoimmune destruction of beta cells may be the key to effective diabetes treatment.

Use a combination of recommendations and clinical judgment to determine the proper calcium and vitamin D requirements for each patient.

Clinical trial results used to support the current recommendations for target blood pressure don't tell the whole story.

Presentation at AACE 2011 focuses on understanding environmental toxins and other disrupters to the endocrine system.

George Bakris, MD, discusses combination therapies for treating hypertension, chronic kidney disease, and diabetes.

Eric Topol, MD, discusses pharmacogenetics, molecular medicine, genomics, and the future of diabetes treatment.

Daniel Von Hoff, MD, discussed novel treatments for rare cancers at the AACE annual meeting.

More than half of patients with type 2 diabetes have experienced hypoglycemia, with many reporting experiences during activities such as driving and working.

Research shows promising results for PPAR modulators, long-acting GLP-1 receptor agonists, SGLT2 inhibitors, and other new classes of diabetes treatments.

Poorly designed trials evaluating hormonal control in critically ill patients may lead to erroneous conclusions with serious consequences for patients.

Molecular medicine is the future of cancer treatment, but also has many potential applications in endocrinology.

Scheduling, session topics, satellite symposia, and other information for physicians planning to attend AACE 2011.

The new clinical practice guidelines on the management of hyperthyroidism that are soon to be released jointly by the ATA and the AACE are a work in progress.

Patients who achieve target LDL-cholesterol levels on statin therapy may still be at risk for cardiovascular disease.

The pros and cons of using the hemoglobin A1C test to diagnose prediabetes and diabetes was the subject of a lively debate at the AACE Meeting.

The benefits of intensive glycemic control on microvascular and neuropathic complications remain clear and well established in both type 1 and type 2 diabetes.

Couples, wherever they live in the world, are interested in having children who are healthy. Unfortunately all of us carry potentially lethal gene mutations.

There are new treatments being investigated for the management of osteoporosis. All show promise, but most still lack definitive data from phase III trials.

Reforming the healthcare system in the United States is about much more than providing basic coverage for all its citizens.

Hyperglycemia among noncritically ill medical and surgical patients is a huge problem in hospitals throughout the United States.

A variety of rapid and reliable tests now exist to diagnose and facilitate the management of pheochromocytoma and primary aldosteronism, but more are needed.

The AACE highlighted a number of studies on a wide range of endocrinology topics from adrenal disorders to metabolic bone disease.

The AACE highlighted a number of studies on a wide range of endocrinology topics from adrenal disorders to metabolic bone disease.